IMHOTEX

• 72110 - Research and experimental development on biotechnology

Imhotex is a virtual drug development company, staffed by senior leaders with extensive experience in the discovery and development of innovative pharmaceuticals. Development of its asset is achieved through engagement of a range of carefully selected service providers with specialist expertise in the key areas required for rapid advancement of the product candidate into the clinic... Imhotex is developing a product candidate for Crohn's Disease. Crohn's Disease (CD) and ulcerative colitis (UC), together inflammatory bowel disease (IBD) are chronic relapsing and remitting afflictions that impose a life-long burden on an increasingly large portion of the population. The incidence of CD is approximately 1 in 500 and the annual costs of treating these patients is approximately $20 billion in the USA... Patients are currently treated with anti-inflammatory agents such as steroids, immunosuppressants and biologics like anti-TNFs. Despite this, a significant proportion of patients undergo..

Also known as: IMHOTEX LIMITED

Registration numbers: 12443280 (CH)

Primary location: Cambridge United Kingdom